Two studies compare triple nucleoside therapy Ziagen® + Combivir® with protease inhibitorplus Combivir® regimens in therapy-naive patients
Two studies compare the efficacy and adherence of the triple nucleoside regimen of Ziagen/Combivir versus PI-containing regimens. Preliminary data show that patients on the Ziagen/Combivir regimen had better viral load suppression, with 68% achieving <400 copies/ml at 24 weeks, compared to 57% on the PI-containing regimen.